Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-31
2006-10-31
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S495000, C548S505000, C548S507000
Reexamination Certificate
active
07129264
ABSTRACT:
The present invention provides compounds of Formula (I):or a stereoisomer or pharmaceutically acceptable salt or hydrate form thereof, wherein the variables A, B, L1, L2, X1, X2, X3, X4and W are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
REFERENCES:
patent: 5886191 (1999-03-01), Dominguez et al.
patent: 6100238 (2000-08-01), Gyorkos et al.
patent: 6239129 (2001-05-01), Lavielle et al.
patent: 6358991 (2002-03-01), Jenkins
patent: 6376486 (2002-04-01), Jenkins et al.
patent: 6429205 (2002-08-01), Jacobson et al.
patent: 6534535 (2003-03-01), Zhu et al.
patent: 2003/0040533 (2003-02-01), Lesieur et al.
patent: WO 99/12903 (1999-03-01), None
patent: WO 99/12935 (1999-03-01), None
patent: WO 00/35886 (2000-06-01), None
patent: WO 01/12187 (2001-02-01), None
patent: WO 2001012600 (2001-02-01), None
patent: WO 01/57020 (2001-08-01), None
patent: WO 02/03986 (2002-01-01), None
patent: WO 02/03989 (2002-01-01), None
patent: WO 2004050637 (2004-06-01), None
patent: WO 2004062661 (2004-07-01), None
patent: WO 2004/080971 (2004-09-01), None
Walsh, P.N., “Platelets and Factor XI Bypass the Contact System of Blood Coagulation”,Thromb. Haemostasis.82(2), pp. 234-242, 1999.
Coleman, R. Contact Activation Pathway: Inflammatory, Fibrinolytic, Anticoagulant, Antiadhesive, and Antiangiogenic Activities,Hemostasis and thrombosis: basic principles and clinical practice,Lippincott Williams & Wilkins, 2001, pp. 103-122.
Schmaier,A.H., “Contact Activation”,Thrombosis and Hemorrhage, Williams&Wilkins,1998, pp. 105-128.
Galiani, D., “Activation of Factor IX by Factor XIa”,Trends in Cardiovascular Medicine,vol. 10, No. 5, 2000, pp. 198-204.
Bouma, B.N. et al., “Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U)”,Thrombosis. Research,2001, 101, pp. 329-354.
Gailani, D., “Gene Targeting in Hemostasis. Factor XI”,Frontiers in Bioscience, 2001, 6, pp. d201-d207.
Gailani, D., et al., “A murine model of factor XI deficiency”,Blood Coagulation and Fibrinolysis, 1997, vol. 8, pp. 134-144.
Minnema, M.C., et al., “Activation of Clotting Factors XI and IX in Patients with Acute Myocardial Infarction”,Arterioscler. Thromb. Vasc. Biol., 2000, 20, pp. 2489-2493.
Murakami, T., et al., “Evaluation of Factor XIa-α1-Antitrypsin in Plasma, a Contact Phase-Activated Coaguation Factor-Inhibitor Complex, in Patients With Coronary Artery Disease”,Arterioscler. Thromb. Vasc. Biol., 1995, 15, pp. 1107-1113.
Meijers, J.C.M., et al., “High Levels of Coagulation Factor XI as a Risk Factor for Venous Thrombosis”,N. Engl. J. Med.,2000, vol. 342, No. 10, pp. 696-701.
Yee et al., “A Novel Series of Selective Leukotriene Antagonists: Exploration and Optimization of the Acidic Region in 1,6-Disubstituted Indoles andIndazoles,” J. Med. Chem., vol. 33, pp. 2437-2451, 1990.
U.S. Appl. No. 10/796,396, filed Mar. 9, 2004, Quan et al.
Bisacchi Gregory S.
Quan Mimi L.
Smallheer Joanne M.
Wang Shuaige
Bristol--Myers Squibb Company
Kosack Joseph R.
Saeed Kamal A.
Sun Jing G.
LandOfFree
Biarylmethyl indolines and indoles as antithromboembolic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biarylmethyl indolines and indoles as antithromboembolic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biarylmethyl indolines and indoles as antithromboembolic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3716126